In vivo prexasertib inhibited the growth of tumor models with various histological backgrounds and potentiate chemotherapy and PARP inhibitors.236–239 The intravenous dose of prexasertib in clinic was determined at MTD, 105 mg/m2 once every 14 days.240 The most common treatment-emergent adverse event (TEAE) was grade 4 neutropenia, typically lasting <5 days. This evidence concerns the gene PARP1 and neutropenia.